Primary Research

 
Stock Quotes for Primary Research top ^
  • Industry: Utilities - Independent Power Producers
  • Sector: Utilities
  • Stock Style: Small Value
Sign-up for 8pen investment picks
  • Industry: Utilities - Independent Power Producers
  • Sector: Utilities
  • Stock Style: Small Value
  • Stock Type: Slow Growth
Sign-up for pri investment picks

 
Fund Quotes for Primary Research top ^
  • Holdings: Intel Corp , Royal Dutch Shell PLC ADR Class A , Encana Corp , Schlumberger NV , Pfizer Inc ,
  • Category: Large Value
  • Morningstar Rating: 2 Stars
Sign-up for ptfdx investment picks
  • Holdings: Roche Holding AG , Samsung Electronics Co Ltd , Sanofi , Bayer AG , GlaxoSmithKline PLC ,
  • Category: Foreign Large Value
  • Morningstar Rating: 4 Stars
Sign-up for tfeqx investment picks
  • Holdings: Roche Holding AG , Samsung Electronics Co Ltd , Sanofi , Bayer AG , GlaxoSmithKline PLC ,
  • Category: Foreign Large Value
  • Morningstar Rating: 4 Stars
Sign-up for us8802105051 investment picks

 
News Articles for Primary Research top ^
OAK BROOK, IL , July 31, 2014 /PRNewswire/ - Primary Energy Recycling Corporation (TSX: PRI) (Primary Energy or the Company) today announced that its Board of Directors has declared a quarterly dividend on the common shares of the Company (the "Shares") in the amount of US$0.07 per Share.
Sign-up for Primary Energy Recycling announces quarterly dividend investment picks
OAK BROOK, IL , July 7, 2014 /PRNewswire/ - Primary Energy Recycling Corporation (TSX: PRI) , a clean energy company that generates revenue from capturing and recycling recoverable heat and byproduct fuels from industrial processes, today announced that it will release its financial results for the second quarter ended June 30, 2014 , after market close on Wednesday, August 6, 2014 .
Sign-up for Primary Energy Recycling Announces Release Date for Second Quarter Results and Conference Call investment picks
Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), and the Department of Environment and Primary Industries (DEPI) of the State of Victoria, announced today several significant steps the organizations are taking together to advance science for agriculture.
Sign-up for Dow AgroSciences, Victorian Department of Environment and Primary Industries Expand Relationship to Advance Science for Agriculture investment picks
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced the presentation of preclinical data demonstrating the promise of DCR-PH1, the Company’s therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1), a rare inherited liver disorder that often results in progressive and severe kidney damage.
Sign-up for Researchers Demonstrate Promise of Dicerna Investigational Therapy in Preclinical Model of Primary Hyperoxaluria Type 1 (PH1) investment picks
Cardinal Health to serve as primary supply chain partner for branded and generic pharmaceuticals under new multi-year agreement MEMPHIS, Tenn.
Sign-up for Fred's And Cardinal Health Announce Primary Supply Agreement investment picks
2014/8/6
In TO920 disseminated at 22:08e today, an error occurred in the "Financial Results" table.
Sign-up for /C O R R E C T I O N -- Primary Energy Recycling Corporation/ investment picks
2014/7/28
Pollard Banknote Named Primary Scratcher Ticket Supplier for the Virginia Lottery Canada NewsWire About Pollard Banknote Pollard Banknote is a leading lottery partner to more than 50 lotteries worldwide, providing high quality instant ticket products, licensed games and strategic marketing and management services for both traditional instant games and the emerging iLottery space of web, mobile and social channels.
Sign-up for Pollard Banknote Named Primary Scratcher Ticket Supplier for the Virginia Lottery investment picks
Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter’s subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]. HYQVIA is the first subcutaneous immune globulin (IG) treatment approved for PI patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion to deliver a full therapeutic dose of IG.
Sign-up for FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency investment picks
2014/9/25
Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO® (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies Canada NewsWire Expect to file in the U.S. in First Half of Q2 2015 Expect to launch in the U.S. in First Half of 2016 Peak U.S. sales ~$500 million+, Peak Global Sales ~$1 billion+ LAVAL, Quebec and SOPHIA ANTIPOLIS, France , Sept.
Sign-up for Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO® (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies investment picks
Eighty Percent of Patients Treated with G-202 had No Tumor Growth at Two Months SAN ANTONIO , July 15, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation.
Sign-up for GenSpera Presents G-202 HCC Clinical Trial Update at 5th Asia-Pacific Primary Liver Cancer Expert Meeting investment picks
Results Published Ahead of Print in the Journal of Acquired Immune Deficiency Syndromes (JAIDS) WALTHAM, Mass.
Sign-up for New Alere™ q Point-of-Care Early Infant Diagnosis Test Prototype Accurately Detects HIV in Infants with High Sensitivity and Specificity in Primary Health Clinics in Mozambique investment picks
Latest Data Sweep from a 285 Patient Subgroup Shows An Impressive 57% Improvement in Overall Survival Data Continues to Validate Phase III OPTIMA Study Design LAWRENCEVILLE, N.J. , July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). As of June 30, 2014 , the latest quarterly Overall Survival (OS) analysis demonstrated that in a large, well bounded, subgroup of patients (n=285, 41% of the study patients), the combination of ThermoDox® and optimized RFA provided a 57% improvement in OS compared to optimized RFA alone.
Sign-up for Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer investment picks
2014/7/22
NEW YORK , July 22, 2014 /PRNewswire/ -- Morningstar Credit Ratings, LLC today assigned its 'MOR CS2' commercial mortgage primary servicer and special servicer rankings for Cohen Financial Services (DE), LLC.
Sign-up for Morningstar Credit Ratings, LLC Assigns 'MOR CS2' Commercial Mortgage Primary Servicer and Special Servicer Rankings for Cohen Financial Services (DE), LLC investment picks
"These positive results enable management to remain optimistic about our ambitious G-202 clinical development program"- Dr.
Sign-up for Media Advisory: GenSpera's G-202 HCC Clinical Trial Presentation from 5th Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting Available investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Primary Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Primary Energy Recycling  |  Next: Prime Rate